Highly sensitive detection of antibody nonspecific interactions using flow cytometry.

ABSTRACT: The rapidly evolving nature of antibody drug development has resulted in technologies that generate vast numbers (hundreds to thousands) of lead antibody candidates during early discovery. These candidates must be rapidly pared down to identify the most drug-like candidates for in-depth analysis of their safety and efficacy, which can only be performed on a limited number of antibodies due to time and resource requirements. One key biophysical property of successful antibody therapeutics is high specificity, defined as low levels of nonspecific binding or polyspecificity. Although there has been some progress in developing assays for detecting antibody polyspecificity, most of these assays are limited by poor sensitivity or assay formats that require proprietary antibody surface display me

SUBMITTER: Makowski EK 

PROVIDER: S-EPMC8317921 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature